Anthos Therapeutics
-
Novartis, Blackstone launch Anthos Therapeutics to develop cardiovascular drugs
Blackstone is investing $250 million, while Novartis is licensing MAA868, a drug for patients who are underserved by existing anti-coagulant drugs.